自身免疫性疾病诊断市场[何种类型（全身自身免疫疾病诊断，本地化自身免疫疾病诊断）;通过最终用户（医院，诊断中心和研究实验室）;和地区]：市场规模和预测，2018年 - 2026年

Report Summary

The global autoimmune disease diagnostics market was estimated at USD 3520.17 Million in 2017 and is anticipated to gain significant traction over coming years.

人体的免疫系统确定了一些侵略者，如病毒，细菌和其他外部外来物质，并攻击那些外国元素以捍卫身体。然而，在某些情况下，身体免疫系统通过将这些细胞视为异物来攻击身体的健康细胞。这种状况被称为自身免疫疾病。自身免疫性疾病导致器官功能的非典型组织生长和偏差。自身免疫发育的主要原因可能是具有环境暴露的人的基因。目前，大约超过80种自身免疫疾病。一些严重的自身免疫疾病是炎症性肠病，类风湿性关节炎，全身性狼疮红斑，1型糖尿病。自身免疫性疾病的准确治疗治疗尚未访问，但只有缓解管理层可用于此疾病。尽管如此，可以通过涉及完全血型的测试，抗体试验，抗核抗体检测他人的诊断，诊断自身免疫疾病。

全球自身免疫性疾病诊断市场主要受到自身免疫疾病人数的增加。例如，根据美国自身免疫相关疾病协会（AARDA）2016年的报告，美国约有5000万人遭受了美国自身免疫疾病。妇女约有75％。此外，对政府举措和公共意识的上升致力于对自身免疫疾病的诊断和护理服务进行预算，是推动全球自身免疫性疾病诊断市场的另一个因素。此外，许多政府以及组织正在投资于研究和开发计划，以发现适当的自身免疫疾病治疗方法，预计该因素有助于在市场上引入新产品，进一步增强自身免疫性疾病诊断市场预测期。例如，引入新的生物标志物，该生物标志物已经确定性是增加自身免疫性疾病的诊断，相应地推动自身免疫性疾病诊断市场的主要因素之一。

However, lack of experience and education of laboratory personnel, the lack of the key specialists, slow turnaround time, and high failure of proper outcome rate are some of the major factors restraining the market growth.

细分分析

The global Autoimmune Disease Diagnostics Market is segmented on the basis of type, end user, and geography. On the basis of type, the global Autoimmune Disease Diagnostics Market is segmented into Systemic autoimmune disease diagnostics and Localized autoimmune disease diagnostics. The systemic autoimmune disease diagnostics is further categorized into Rheumatoid arthritis, Ankylosing spondylitis, Systemic lupus erythematosus (SLE), and others. On the other side, the Localized autoimmune disease diagnostics is further categorized into Multiple sclerosis, Type 1 diabetes, Hashimoto's Thyroiditis, Idiopathic thrombocytopenic purpura, and Others. In 2017, Localized disease diagnostics dominated the overall market. The dominance is majorly attributed to the existence of large process measurements and moderately higher patient awareness level in comparison to systemic diseases. On the basis of end users, the global autoimmune disease diagnostics market is segmented into Hospitals, Diagnostics Centers, and Research Laboratories.

区域分析

In terms of geography, North America is estimated to dominate the global autoimmune disease diagnostics market. The dominance is majorly attributed to increasing prevalence of some of the common autoimmune diseases such as type1 diabetes and rheumatoid arthritis. The surge in funding by private and government organizations, growing regulatory scenario observed by World Health Organization (WHO), and advancement in technology are some of the other factors driving the growth of the autoimmune disease diagnostics market in North America. However, the Asia Pacific is expected to be a fast emerging region in the global autoimmune disease diagnostics market. The swift growth is attributed to the increasing incidences of the autoimmune disease, large investments in R&D and surging government support to control the autoimmune disease. the Asia Pacific is expected to dominate the market during the forecast period.

竞争格局

大公司都在关注小firms with a working methodology of securing the end goal to manage position in the market and are associated with mergers and acquisitions, key joint efforts, and novel item advancement to pick up profit share in the business. Some major key players in global Autoimmune Disease Diagnostics Market includes F. Hoffmann-La Roche Ltd, Siemens Healthineers, Abbott Laboratories, Beckman Coulter, Inc., SQI Diagnostics, Quest Diagnostics, EUROIMMUN AG, AESKU.Diagnostics GmbH & Co. KG, INOVA Diagnostics, Inc., Crescendo Bioscience, Inc., bioMerieux SA, Bio-Rad Laboratories, Inc., and Hemagen Diagnostics, Inc. among others.